|
 The plan includes closing its research and development center in the
coastal city of Netanya, selling its logistics center in Shoham and
laying off a third of its 6,800 workers in Israel, Calcalist said,
citing people familiar with the matter.
A spokeswoman for Teva declined to comment.
Teva, the world's largest generic drug maker, employs more than
56,000 people. Last week, Bloomberg reported that the firm was
considering cutting up to 10,000 jobs to reduce costs by $1.5
billion to $2 billion in the next two years.
Teva said on Tuesday that Yitzhak Peterburg, who previously served
as the company's chairman and interim CEO, had resigned from its
board, effective immediately.
Saddled with nearly $35 billion in debt since acquiring Allergan's
Actavis generic drug business for $40.5 billion, Teva witnessed a
series of changes after Kare Schultz joined the company on Nov. 1 as
its new chief executive.
[to top of second column] |
Schultz ousted top division heads last month and said he would
combine the firm’s generic and specialty drug businesses. He had
also said the company was working on a detailed restructuring plan
to be unveiled in mid-December.
(Reporting by Tova Cohen; Editing by Edmund Blair)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
